Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models

Figure 3

Immunohistochemistry analyses for TTR in stomachs from TTR mice treated with doxycycline and TUDCA. Groups of animals analyzed: in the upper row: control mice (n = 7); mice receiving doxycycline alone (40 mg/Kg/day; n = 9); mice receiving TUDCA alone (500 mg/Kg/day; n = 7); in the lower row: mice receiving either high dosages of doxycycline/TUDCA (40 mg/Kg/day and 500 mg/Kg/day, respectively; n = 7) or receiving low dosages of doxycycline/TUDCA (8 mg/Kg/day and 50 mg/Kg/day, respectively; n = 8). The combined scheme involved the administration of the referred dosage of doxycycline for 15 days, followed by the administration of the referred dosage of TUDCA for 30 days. The cycle was repeated twice; for the individual drug administration, during the interruption periods, mice were receiving water alone. Scale bar = 200 μm; Histogram: quantification of the levels of the referred marker, as described in material and methods.*P < 0.05.

Back to article page